Nicotinic acid mononucleotide, a SARM1 inhibitor (IC50 93.3 μM), is an intermediate in NAD+ biosynthesis. It exhibits axon-protective effects, delays axonal degeneration, elevates NAD+ levels, and boosts Sirt1 activity. This compound improves myocardial capillary density, alleviates myocardial fibrosis, and reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD+ levels. It is relevant for research in cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases, and Huntington's disease.
- SARM1 inhibitor.
- NAD+ biosynthesis intermediate.
- Axon-protective and delays axonal degeneration.
- Elevates NAD+ levels and enhances Sirt1 activity.
- Improves myocardial capillary density and alleviates myocardial fibrosis.
- Reverses diabetic cardiomyopathy in diabetic mice via increased NAD+ levels.
- Research applications include cancer, multiple sclerosis, and neurodegenerative diseases.